二磷酸盐引起颌骨骨坏死的机制

doi:10.13701/j.cnki.kqyxyj.2018.08.005

摘要/Abstract

摘要： 二磷酸盐(又称双磷酸盐)是一组用于治疗骨质疏松及肿瘤等疾病的药物,临床中可见采用二磷酸盐治疗的患者出现颌骨骨坏死的并发症。二磷酸盐引发颌骨骨坏死的临床表现及发生率的报道较多,然而关于其发病原因及机制的研究较少,本文对此作一综述。

关键词: 二磷酸盐, 机制, 颌骨, 骨坏死

Abstract: Bisphosphonate is a group of drugs commonly used for the treatment of osteoporosis and tumors. The complication of bisphosphonate is osteonecrosis of the jaw. The clinical manifestation and incidence of bisphosphonate are fully reported at present. However, the pathogenesis and mechanism are still remaining insufficient.

Key words: Bisphosphonate, Mechanism, Jaw, Osteonecrosis

孙晋, 张强. 二磷酸盐引起颌骨骨坏死的机制[J]. 口腔医学研究, 2018, 34(8): 818-820.

SUN Jin, ZHANG Qiang. Bisphosphonate Leads to Osteonecrosis of Jaw: A Review of Mechanism[J]. Journal of Oral Science Research, 2018, 34(8): 818-820.

参考文献

[1] Russell RG. Bisphosphonates: the first 40 years [J]. Bone, 2011, 49(1)∶2-19
[2] Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate induced exposed bone (osteonecrosis/osteoporosis) of the jaws: risk factors, recognition, prevention and treatment [J]. J Oral Maxillofac Surg,2005,63(11)∶1567-1575
[3] Kalra S, Jain V. Dental complications and management of patients on bisphosphonate therapy: A review article [J]. Oral Biol Craniofac Res,2013,3(1)∶25-30
[4] 李阳,高永波.种植术后双膦酸盐相关性颌骨坏死处理体会[J].口腔颌面外科杂志,2016,26(6)∶427-430
[5] Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta [J]. Cochrane Database Syst Rev, 2014,(7):CD005088
[6] Fleisch H. Biphosphonate as a therapeutic drug-experimental studies and clinical application [J]. Ther Umsch,1985, 42(6)∶366-375
[7] Wypij JM, HellerDA. Pamidronate disodium for palliative therapy of feline bone-invasive tumors [J]. Vet Med Int,2004,2014∶675172
[8] Bittner T, Lorbeer N, Reuther T, et al. Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: A case report and review on the prevention and treatment of bisphosphonate-related osteone crosis of the jaw [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2012,113(1)∶41-47
[9] Russell RGG, Xia Z, Dunford JE, et al. Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy [J]. Ann N Y Acad Sci,2007,1117(1)∶209-257
[10] Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption [J]. Adv Drug Deliv Rev,2000,42(3)∶175-179
[11] King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates [J]. Pharmacotherapy, 2008, 28(5):667-677
[12] 徐佑兰,邹海啸,李晶.颌骨放射性骨坏死相关危险因素分析[J].口腔医学研究,2014,30(6)∶563-565
[13] Qamheya AHA, Yeniyol S, Arisan V. Bisphosphonate-related osteonecrosis of the jaw and dental implants [J]. J Istanb Univ Fac Dent,2016,50(1)∶59-64
[14] Soucacos PN, Kokkalis ZT, Piagkou M, et al. Vascularized bone grafts for the management of skeletal defects in orthopaedic trauma and reconstructive surgery [J]. Injury,2013,44(Suppl 1)∶S70-S75
[15] Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis [J]. Endocrinol Metab Clin North Am, 2012, 41(3)∶595-611
[16] 王根林,杨惠林,朱雪松,等.骨质疏松性椎体骨坏死的诊断及椎体后凸成形术治疗[J].中国脊柱脊髓杂志,2013,23(3)∶228-232
[17] 童培建,吴云刚,肖鲁伟,等.高凝、低纤和高脂血症在实验性激素性股骨头坏死发生中的作用[J].中国骨伤,2002,15(6)∶343-346
[18] Harrell DB, Caradonna E, Mazzucco L, et al. Non-hematopoietic essential functions of bone marrow cells: a review of scientific and clinical literature and rationale for treating bone defects [J]. Orthop Rev (Pavia),2015,7(4)∶5691
[19] Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis [J]. Ther Adv Musculoskelet Dis,2016,8(6)∶225-235
[20] Haraguchi R, Kitazawa R, Mori K, et al. sFRP4-dependent Wnt signal modulation is critical for bone remodeling during postnatal development and age-related bone loss [J]. Sci Rep,2016,6∶25198
[21] Kim DS, Kim JH, Ohe JY, et al. Bisphosphonate-related osteonecrosis of the jaw in a patient with osteoporosis following treatment of testicular cancer: a case report [J]. J Korean Assoc Oral Maxillofac Surg,2015,41(6)∶327-331
[22] Kim HJ, Park TJ, Ahn KM. Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases [J]. Maxillofac Plast Reconstr Surg,2016,38(1)∶6
[23] Benhamou CL. Effects of osteoporosis medications on bone quality [J]. Joint Bone Spine,2007,74(1)∶39-47
[24] Saia G, Blandamura S, Bettini G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction [J]. J Oral Maxillofac Surg,2010,68(4)∶797-804
[25] Saldanha S, Shenoy VK, Eachampati P, et al. Dental implications of bisphosphonate-related osteonecrosis [J]. Gerodontology,2012,29(3)∶177-187
[26] Gao SY, Zheng GS, Wang L, et al. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB [J]. PLoS One,2017,12(6)∶e0179248
[27] Hoefert S,Sade HC,Munz A,et al.Effect of bisphosphonates on macrophagic THP-1 cell survival in bisphosphonate-related osteonecrosis of the jaw (BRONJ) [J]. Oral Surg Oral Med Oral Pathol Oral Radiol,2016,121(3)∶222
[28] Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab [J]. Osteoporos Int,2010,21(11)∶1963-1964
[29] Endo Y, Kumamoto H, Nakamura M, et al. Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the Jaw (BRONJ) [J]. Biol Pharm Bull,2017,40(6)∶739-750
[30] 马泽云,王衣祥.建立大鼠双膦酸盐相关颌骨骨坏死模型并初步分析其发病原因[J].北京大学学报(医学版),2014,46(6)∶945-949
[31] Xu Y, Sun J, Yang X, et al. Pamidronate disodium leads to bone necrosis via suppression of Wnt/β-catenin signaling in human bone marrow mesenchymal stem cells in vitro [J]. J Oral Maxillofac Surg,2017,75(10)∶2135-2143
[32] Woo SB, Hell Stein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw [J]. Ann Intern Med,2008, 109(6)∶367-373